[go: up one dir, main page]

MX2018005872A - Profarmacos de acido nucleico. - Google Patents

Profarmacos de acido nucleico.

Info

Publication number
MX2018005872A
MX2018005872A MX2018005872A MX2018005872A MX2018005872A MX 2018005872 A MX2018005872 A MX 2018005872A MX 2018005872 A MX2018005872 A MX 2018005872A MX 2018005872 A MX2018005872 A MX 2018005872A MX 2018005872 A MX2018005872 A MX 2018005872A
Authority
MX
Mexico
Prior art keywords
nucleic acid
acid prodrugs
prodrugs
relates
treatment
Prior art date
Application number
MX2018005872A
Other languages
English (en)
Inventor
Thomas Stephen
Crutcher Patrick
Original Assignee
Ichorion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ichorion Therapeutics Inc filed Critical Ichorion Therapeutics Inc
Publication of MX2018005872A publication Critical patent/MX2018005872A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

La invención se refiere a profármacos de nucleótido y preparaciones farmacéuticas de los mismos. La invención se refiere además a métodos de tratamiento empleando los nuevos profármacos de la invención.
MX2018005872A 2015-11-16 2016-11-16 Profarmacos de acido nucleico. MX2018005872A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562255829P 2015-11-16 2015-11-16
PCT/US2016/062271 WO2017087517A1 (en) 2015-11-16 2016-11-16 Nucleic acid prodrugs

Publications (1)

Publication Number Publication Date
MX2018005872A true MX2018005872A (es) 2019-05-16

Family

ID=58717774

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018005872A MX2018005872A (es) 2015-11-16 2016-11-16 Profarmacos de acido nucleico.

Country Status (9)

Country Link
US (2) US10745435B2 (es)
EP (1) EP3377512A4 (es)
JP (1) JP7019585B2 (es)
CN (1) CN108431016A (es)
AU (1) AU2016355429B2 (es)
BR (1) BR112018009946A8 (es)
CA (1) CA3005444A1 (es)
MX (1) MX2018005872A (es)
WO (1) WO2017087517A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3377512A4 (en) * 2015-11-16 2019-09-18 Ichorion Therapeutics, Inc. Nucleic Acid PRODRUGS
GB201709471D0 (en) * 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
US20210139525A1 (en) * 2018-01-05 2021-05-13 Cerecor, Inc. Nucleotide prodrugs
JP7620781B2 (ja) * 2018-04-12 2025-01-24 ユーシービー バイオサイエンシズ，インコーポレイテッド 不均衡なヌクレオチドプールによって引き起こされた疾患を治療するためのデオキシヌクレオシドのプロドラッグ
CN112778310B (zh) 2020-04-20 2025-05-30 中国科学院上海药物研究所 核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用
CN117500510A (zh) * 2021-06-18 2024-02-02 周格尼克斯公司 用于治疗由失衡的核苷酸池引起的线粒体疾病的脱氧核苷的前药

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
WO1999006023A1 (en) 1997-07-29 1999-02-11 Alcon Laboratories, Inc. Ophthalmic compositions containing galactomannan polymers and borate
US7462605B2 (en) * 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
CA2318920A1 (en) 1998-01-29 1999-08-05 James W. Young Pharmaceutical uses of optically pure (-)-bupropion
IL147750A0 (en) 1999-07-22 2002-08-14 Newbiotics Inc Enzyme catalyzed therapeutic activation
US6420407B1 (en) * 1999-09-16 2002-07-16 Gerald Horn Ophthalmic formulation which modulates dilation
US6730065B1 (en) * 2000-09-15 2004-05-04 Ocularis Pharma, Inc. Night vision composition
US6291498B1 (en) * 1999-09-16 2001-09-18 Gerald Horn Method for optimizing pupil size using alpha antagonist
US8889112B2 (en) * 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
US6933289B2 (en) * 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
ATE444732T1 (de) * 2003-08-07 2009-10-15 Allergan Inc Zusammensetzungen zur abgabe von therapeutika in die augen und verfahren zu ihrer herstellung und verwendung
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
GB0505781D0 (en) 2005-03-21 2005-04-27 Univ Cardiff Chemical compounds
US7888330B2 (en) * 2005-11-09 2011-02-15 Wayne State University Phosphoramidate derivatives of FAU
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
HUE029022T2 (en) 2011-03-01 2017-02-28 Nucana Biomed Ltd Phosphoramidate derivatives of 5-fluoro-2'-deoxyuridine for use in the treatment of cancer
WO2016134054A1 (en) * 2015-02-18 2016-08-25 Abbvie Inc. Anti-viral compounds
US10611790B2 (en) 2015-11-02 2020-04-07 Mitobridge, Inc. Nicotinamide riboside and nicotinamide mononucleotide derivatives for use in the treatments of mitochondrial-related diseases
EP3377512A4 (en) * 2015-11-16 2019-09-18 Ichorion Therapeutics, Inc. Nucleic Acid PRODRUGS
US20210139525A1 (en) * 2018-01-05 2021-05-13 Cerecor, Inc. Nucleotide prodrugs

Also Published As

Publication number Publication date
US10745435B2 (en) 2020-08-18
AU2016355429A1 (en) 2018-05-31
CN108431016A (zh) 2018-08-21
AU2016355429B2 (en) 2021-05-06
JP7019585B2 (ja) 2022-02-15
BR112018009946A8 (pt) 2019-02-26
US20180346508A1 (en) 2018-12-06
US11479576B2 (en) 2022-10-25
JP2018533634A (ja) 2018-11-15
EP3377512A1 (en) 2018-09-26
EP3377512A4 (en) 2019-09-18
US20210101923A1 (en) 2021-04-08
CA3005444A1 (en) 2017-05-26
WO2017087517A1 (en) 2017-05-26
BR112018009946A2 (pt) 2018-11-06

Similar Documents

Publication Publication Date Title
ZA202004557B (en) Modulatory polynucleotides
PH12018501378A1 (en) Compositions and methods for the treatment of hemoglobinopathies
IL264439A (en) Nucleic acid products and methods of administering them
MX2024013018A (es) Dianas terapeuticas para la correccion del gen de la distrofina humana por edicion genica y metodos de uso
IL256905A (en) Methods for Amplifying Nucleic Acid Sequences
EP4620519A3 (en) Methods and compositions relating to chondrisomes from blood products
SG11201707663SA (en) Lyophilization of rna
PH12016502555A1 (en) Methods of preparing substituted nucleotide analogs
SG11201707832RA (en) Rna containing composition for treatment of tumor diseases
EP3256585A4 (en) Nucleic acid products and methods of administration thereof
WO2015112896A3 (en) Methods and compositions for sequences guiding cas9 targeting
EP3995581A3 (en) Oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders
EP3234200A4 (en) Compositions and methods for targeted depletion, enrichment, and partitioning of nucleic acids using crispr/cas system proteins
WO2016065349A8 (en) Short non-coding protein regulatory rnas (sprrnas) and methods of use
PH12016501441A1 (en) Chimeric alkaline phosphate-like proteins
MX2017004448A (es) Compuestos anti-factor de necrosis tumoral (tnf).
HK1243714A1 (zh) 制备取代的核苷类似物的方法
MX2018005872A (es) Profarmacos de acido nucleico.
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
TW201613949A (en) Targeting microRNAs for metabolic disorders
MX395492B (es) Usos terapeuticos de l-4 cloroquinurenina.
MX2024000004A (es) Proteinas de fusion de inhibidor de tripsina urinaria (uti).
EA201791845A1 (ru) Твердые формы менахинолов
PH12016501326A1 (en) (s)-3'-methyl-abscisic acid and esters thereof
EP3631006A4 (en) DNA STABILIZATION OF RNA